Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies by Trujillo, Angelica et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 128608, 9 pages
doi:10.1155/2012/128608
Review Article
Angiogenesisin Acute Myeloid Leukemiaand
Opportunitiesfor Novel Therapies
AngelicaTrujillo,ChristieMcGee,andChristopher R.Cogle
Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville,
FL 32610-0278, USA
Correspondence should be addressed to Christopher R. Cogle, c@uﬂ.edu
Received 2 May 2011; Revised 3 July 2011; Accepted 5 July 2011
Academic Editor: Arkadiusz Dudek
Copyright © 2012 Angelica Trujillo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Acute myeloid leukemia (AML) arises from neoplastic transformation of hematopoietic stem and progenitor cells, and relapsed
disease remains one of the greater challenges in treating this hematologic malignancy. This paper focuses on angiogenic aspects
of AML including the signiﬁcance and prognostic value of bone marrow microvessel density and circulating cytokine levels. We
show three general mechanisms whereby AML exploits angiogenic pathways, including direct induction of angiogenesis, paracrine
regulation, and autocrine stimulation. We also present early evidence that leukemia cells contribute directly to vascular endothelia.
Novel treatment strategies are proposed, and a review of relevant antiangiogenic clinical trials is presented. By understanding how
blood vessels can serve as a reservoir for refractory and relapsed AML, new diagnostics and promising treatment strategies can be
developed.
1.Introduction
Acute myeloid leukemia (AML) is a cancer of the bone
marrowcharacterizedbyamutationinahematopoieticstem
or progenitor cell (HSPC), which develops into a highly
proliferative accumulation of dysfunctional and immature
myeloid cells. These abnormal cells eventually dominate
hematopoietic niches like the bone marrow and result in
abnormal peripheral blood counts (anemia, thrombocy-
topenia, leukocytosis due to high number of myeloblasts
number and/or neutropenia) [1]. Initial disease remission
can be achieved in 30–70% of AML patients after standard
induction chemotherapy regimens such as 7 + 3 (seven days
of cytarabine and 3 days of an anthracycline). However,
refractory and relapsed disease remains a major challenge
in all patients, especially in older individuals. In patients 60
years and older, the 5-year survival prognosis for AML is
only20%withthemajorityofpatientssuccumbingtodisease
relapse [2, 3]. Mechanisms for AML relapse are related
to leukemia cell insensitivity and potential sanctuary sites.
When considering that functional blood vessel networks are
essential to these mechanisms of relapse, the investigation of
angiogenesis in leukemia is highly signiﬁcant.
Until recently, leukemia studies have focused primarily
on the leukemia cell. However, with mounting evidence
showing the importance of the bone marrow microen-
vironment in regulating hematopoiesis, it is necessary to
broaden the scope of investigation beyond the leukemia cell.
Abetterunderstandingofthepathobiologysurroundingand
supporting leukemia cell survival has great potential to lead
to promising new therapies.
2.EndothelialCellsinSupport ofLeukemia
The importance of the cancer microenvironment is widely
recognized in solid tumors. Cancer cells interact with the
stromal microenvironment in complex ways to promote
their own survival and proliferation. However, in the case of
hematologic malignancies like AML, the leukemia microen-
vironment is highly dynamic. The typical leukemia niche is
within the bone marrow microenvironment. But AML cells
can also migrate systemically to other organs that support
hematopoiesis, such as the liver and spleen [4]. Monocytic
AML subtypes (M4 and M5 FAB subtypes) can also migrate
across blood-organ barriers and into privileged areas such as
the central nervous system.2 Journal of Oncology
Although the complete model of the bone marrow mi-
croenvironment is not yet fully understood, it has been
simplistically divided into three compartments: an endosteal
niche that maintains quiescent hematopoietic stem cells, a
vascular niche which regulates entry and exit from the bone
marrow, and the central marrow space ﬁlled with various
hematopoietic progenitors in the process of diﬀerentiation
[5]( Figure 1).
One of the earlier investigations in the relationship
between AML cells and the vascular niche was performed
by Fiedler et al. [6]. These investigators found that a large
proportion of AML patients had disease that expressed vas-
cular endothelial growth factor (VEGF), as well as VEGFR1
and VEGFR2. They also found that VEGF induced human
umbilical vein endothelial cells (HUVECs) secrete GM-CSF,
which is a known mitogen for AML cells. Together, these
results were one of the ﬁrst to suggest that AML cells (i)
exploit angiogenic signaling for autocrine stimulation and
(ii) provoke endothelial cells to secrete proleukemic factors
for survival and proliferation.
Recent evidence indicates that leukemia cells, like tumor
cells, depend on angiogenesis in the bone marrow. Clinically,
increased angiogenesis has been reported in the bone mar-
row of patients with AML. Hussong et al. stained bone mar-
row biopsies for blood vessels in 20 patients with untreated
AML, compared with 20 control patients and quantiﬁed
the number of vessels/mm in each case [7]. They found
signiﬁcantly increased microvessel density (MVD) in the
bone marrow of AML patients (P<0.001), suggesting a role
of angiogenesis in AML. This is particularly signiﬁcant when
consideringthestrongpositivecorrelationbetweenincreased
bone marrow vasculature and overall survival of leukemia
[8, 9]. A higher microvessel density predicted for poor
prognosis and suggests that blood vessel-AML interactions
may contribute to refractory disease [10].
Endothelial cellssupport adhesion and transmigration of
subsetsofnormalCD34+HSPCs.Invitrostudieshaveshown
that upon transwell or direct coculture with HUVECs, AML
blasts proliferate to a higher degree and are less susceptible
to traditional chemotherapeutic agents such as cytarabine
[11]. We have found similar results when coculturing human
promyelocytic leukemia cells (HL60) with HUVECs and
then exposing the cells to cytarabine. HUVECs protect
AML cells from chemotherapy (Figure 2). Together, these
results provide compelling evidence that endothelial cells are
protective of leukemia and may be a site of leukemia reini-
tiation after chemotherapy. Although the protective eﬀect
of endothelial cells on leukemic myeloblasts is evident, a
thorough understanding of the detailed interactions and
mechanisms is necessary in order to rationally design new
therapeutic strategies.
While endothelial cells enhance leukemia proliferation,
emerging evidence indicates that leukemia cells may have a
reciprocal eﬀect of enhancing endothelial cell proliferation.
Hatﬁeld et al. investigated the hypothesis of interdependence
using transwell and direct contact experiments between
primary AML cells and dermal microvascular endothelial
cells (DMVECs). 3H-Thymidine incorporation assays were
used to quantify proliferation of endothelial cells. Their
results showed enhanced endothelial cell proliferation in
transwell coculture with AML blasts [12]. At the very least,
thiscodependenceismediatedbysecretedcytokinesbetween
leukemia cells and endothelial cells. Cytokines that are
involved in this bidirectional crosstalk include, for example,
VEGF, angiopoietins, GM-CSF, CXCL8, and IL-6. A study by
Kruizinga et al. [13], evaluated the leukemia cell expression
levels of several VEGF isoforms in a pediatric AML popula-
tion. The study used PCR arrays to analyze AML myeloblast
cells for the presence of the cytokines. Various isoforms of
VEGF including VEGF-121, VEGF-165, and VEGF-189 were
expressed in the AML cells. Particularly, the VEGF-165 and
VEGF-189 isoforms stimulated endothelial proliferation and
angiogenesis. However, correlations between VEGF mRNA
isoform expression levels and known prognostic factors were
not found, nor was there a relationship between VEGF ex-
pression and overall survival or relapse-free survival.
With ECs promoting AML cells, and AML cells pro-
moting ECs, a cyclical positive feedback loop is established
and strongly favors the potential for refractory and relapsed
disease (Figure 3).
Clinically, increased levels of circulating angiogenic fac-
tors correlate with increased angiogenesis in the bone
marrow [14] and are high-risk indicators of disease relapse
and early mortality [15]. Some of these circulating pro-
angiogenic factors include VEGF and the angiopoietins. The
clinical relevance of other angiogenic mediators, such as
basic ﬁbroblast growth factor (bFGF) and IL-6, has yet to be
deﬁned. The presence of angiogenic mediators in leukemia
is complicated by the variabilities of gene expression and
factor secretion. Cytokine levels vary on a patient-by-patient
(disease-by-disease) basis, but evaluating the presence of
these cytokines can be used as a prognostic indicator.
Hou et al. [16] assessed the expression of a few of these
cytokines in mononuclear cells of the bone marrow in
126 newly diagnosed AML patients prior to treatment to
correlate prognostic outcome. By PCR screening, they found
that a high level of pretreatment angiopoietin-2 (Ang-2)
was a prognostic indicator of poor outcome. There is contra-
ry evidence from others [17] that showed that pretreatment
levels of Ang-2 were a prognostic indicator of good clinical
outcomes. However, in common between these seemingly
conﬂicting reports were the observations that in the presence
of high VEGF-A levels, high Ang-2 correlated with poor
outcome. Thus, the signiﬁcance of Ang-2 in AML is complex
and most likely inﬂuenced by VEGF activity. The angiopoi-
etin/Tie2 axis may be important in AML and certainly needs
further deﬁnition.
3.Leukemia CellswithEndothelialCell-Like
Phenotype and Function
The ability of leukemia cells to respond to angiogenic signals
from endothelial cells suggests a close relationship between
the two cell types. In fact, AML cells from patients have been
reported to express VEGF and VEGFRs [6, 13, 18]. Fiedler et
al. were the ﬁrst to report that primary AML cells can express
VEGF, VEGFR1, and VEGFR2. A greater proportion of AMLJournal of Oncology 3
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Figure 1: Acute Myeloid Leukemia Cells Within the Bone Marrow Microenvironment. The bone marrow niche can be simplistically divided
intotheendostealnicheorosteoblasticnichewhichislocatedontheinnerbonesurface.Hematopoieticstemcells(HSCs)havebeenfoundto
residehereinaquiescentstate.Thevascularnicheismadeupacentralsinusoidandlinedbyendothelialcells,macrophages,andperivascular
cells. In the central marrow region, between the endosteal niche and vascular niche, acute myeloid leukemia (AML) cells hijiack the entire
bone marrow anatomy and induce angiogenesis. The location of AML initiation and relapse within the bone marrow has yet to be deﬁned.
patients had disease that expressed VEGFR1 compared to
VEGFR2 [6]. Padro et al. also screened AML patients, but
found that VEGFR2 was more commonly expressed on AML
myeloblasts [19]. Together these data support the notion
that AML blasts can exhibit a hybrid EC phenotype and
that the coexpression of EC surface proteins is variable. The
variability of VEGFR expression on AML cells introduces the
possibility of a personalized medicine approach to treating
AML. For example, in patients who have AML that expresses
VEGFRs, treatment with anti-VEGF agents may bring about
improved outcomes.
GiventhatAMLcellscansecreteVEGFandexpressVEG-
FRs, it stands to reason that AML cells may beneﬁt from an
autocrineloop.Indeed,investigatorshavereportedapossible
autocrine loop including VEGF produced by leukemia cells
and their own VEGF receptors. In particular, VEGFR2+
AMLcellsweretreatedwithVEGFR2neutralizingantibodies
in serum-free growth conditions. Blocking VEGFR2 resulted
in decreased leukemic cell growth, supporting the notion of
a VEGF/VEGFR2 autocrine loop [20].
The angiopoietin/Tie2 axis represents another potential
autocrine loop in AML. We and others have found that
certain myeloid leukemia cell lines, namely, K-562, express
angiopoietin-1 (Ang-1), Ang-2, and their receptor, Tie2.
Primary human AML specimens have also been reported to
express these endothelial cell associated factors and receptor
[21]. An in vitro study by Reikvam et al. found that block-
ing angiopoietin interactions with the Tie2 receptor using
antibodies led to marked decreases in AML cell prolifer-
ation [22]. Interestingly, they found that some primary
AML specimens were dependent on autocrine stimulation
in order to proliferate, whereas others that did express
the angiopoietins and Tie2 proliferated independently of
autocrine stimulation. Yet to be deﬁned is the eﬀect of
angiopoietin peptibodies such as AMG386 (Genetech) in
hematologic malignancies. Clinical studies have begun using
these peptibodies in prostate and ovarian cancers [23].
Another explanation for AML myeloblasts that coexpress
EC phenotype is the possibility of fusion. Studies by Skinner
etal. [24] further explored this idea using an in vivo model of
primary human AML cells into immunocompromised mice.
Hepatic sinusoids were lined by hybrid human AML-murine
ECs (AML-EC). Moreover, these fused AML-ECs contained
separated human DNA and murine DNA typically found
in syncytia. Yet to be determined is whether the expression
of EC proteins endows AML myeloblasts with resistance4 Journal of Oncology
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Figure 2: Endothelial Cells Protect Acute Myeloid Leukemia Cells
from Chemotherapy. Human acute promyelocytic leukemia cells
(HL60) were cultured in two conditions: over plastic and in the
presence of human umbilical vein endothelial cells (HUVECs).
The leukemia cells were then exposed to cytarabine chemotherapy,
which is commonly administered to patients with AML. Cell pro-
liferation was subsequently measured by XTT assay. HL60 cells in
coculture with HUVECs showed no decrease in cell proliferation
after chemotherapy exposure (NS) as compared to HL60 cells
cultured over plastic (P<0.05).
to chemotherapy. If AML-EC hybrids are more resistant
to chemotherapy and can regenerate and proliferate AML
cell population, then these cells may represent sources of
refractory and relapsed disease.
4. Leukemia Hemangioblast Activity: Leukemia
Cell Differentiation into Endothelial Cells
Blood and blood vessels are closely linked in developmental
biology. In the embryo, the hematopoietic and endothelial
lineages are generated from a common mesodermal progen-
itor, the hemangioblast [25, 26]. Our group and others have
demonstrated that adult hematopoietic stem and progenitor
cells also exhibit this hemangioblast activity [27–30]. Given
that AML cells arise from malignant hematopoietic stem and
progenitor cells, it is therefore possible that there may also
be a leukemia hemangioblast—generating both malignant
leukocytes and malignant ECs.
In one report, a subpopulation of vascular progenitor
cells (VEGFR2+ CD31− CD34−) harboring the BCR/ABL
gene fusion was identiﬁed in the BM of patients with CML
[31]. These cells possessed the potential to form malignant
hematopoietic and endothelial cells in vitro at the single-
cell level. Moreover, when transplanted into NOD/scid mice,
these VEGFR2+ CD31− CD34− cells were capable of repro-
ducibly transferring CML to transplanted mice and gen-
erating ECs within blood vessels that expressed BCR/ABL.
In other studies, it was shown that transformed genotypes
including BCR/ABL and the Janus kinase 2 (JAK2) V617F
mutation are not readily found in colonies generated in
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Figure 3: Multiple Mechanisms of Angiogenic Pathways Regulate
Acute Myleoid Leukemia Survival and Proliferation. Acute myeloid
leukemia cells exploit angiogenic mechanisms by (1) inducing
angiogenesis directly, (2) expressing receptors for speciﬁc angio-
genic growth factors (paracrine regulation), and (3) secreting their
own angiogenic factors for their own angiogenic growth factor
receptors (autocrine stimulation). Thus, angiogenesis has both
cell-extrinsic and cell-intrinsic signiﬁcance in leukemia. Stem cell
factor (SCF), platelet-derived growth factor (PDGF), and vascular
endothelial growth factor (VEGF) are a few of many yet to be
deﬁned angiogenic factors that regulate leukemia cell survival and
proliferation.
endothelial colony forming cell (ECFC) culture conditions,
whereas angiogenic monocytes that form CFU-Hill colonies
can harbor such mutations [32, 33]. Together, these results
demonstratetheexistenceofanadulthemangioblastpopula-
tioneveninsettingsofhematologicalmalignancies;however,
these data also suggest that ECs harboring cytogenetic
mutations may not be derived from putative endothelial
progenitor cells (EPCs), which are deﬁned by their ability
to form ECFC colonies, but instead from a population of
hematopoietic-derived cells.
Certainly, the existence of a bipotential malignant hema-
topoietic stem cell could explain a source of relapsed disease
and would represent a new target for therapy.
5. PotentialNovel Therapeutic
ApproachestoTargetingLeukemiaand
Endothelial CellInteractions
The importance of angiogenesis in AML has led to clinical
studies of vascular targeting agents in patients with AML
(Table 1). Both angio-inhibitory and vascular disrupting
strategies are being studied.
Given the presence of VEGF in AML and signs of in-
creased angiogenesis in the bone marrow, investigators have
tested anti-VEGF strategies for the treatment of AML. Beva-
cizumab (anti-VEGF-A antibodies, Avastin) brings about
modest clinical eﬃcacy in the treatment of colon cancer
when combined with cytotoxic chemotherapy [45]. In
the case of AML, bevacizumab was proposed to inhibitJournal of Oncology 5
Table 1: Vascular targeting strategies for patients with acute myeloid leukemia.
Agent References Target Phase of
clinical study
# of Patients
in AML
trial(s)
Clinical activity
Bevacizumab [34, 35] VEGF-A Phase 2 48, 9
None as monotherapy; minimal
when combined with
chemotherapy
Aﬂibercept [36] VEGF-A, VEGF-B, PlGF Preclinical
Sunitinib [37] VEGFR-1,-2,-3, PDGFRs, c-KIT,
FLT3, CSF-1, RET Phase 1 15 Minimal as monotherapy
Semaxanib [38] VEGFR-1, -2, c-KIT, FLT3 Phase 2 6 Minimal as monotherapy
Sorafenib [39–41] FLT3, VEGFR-2, -3, PDGFR, Raf,
c-KIT Phase 3 127 None
Axitinib [42] VEGFR-1, -2, -3, PDGFR-β,
c-KIT Phase 2 12 Minimal as monotherapy
Cediranib [37] VEGFR-1, -2, -3, PDGFR-β,
c-KIT Phase 1 35 Modest as monotherapy
Vatalinib [43] VEGFR-1, -2, -3, PDGFR-β,
c-KIT, FMS Phase 1 17
None with monotherapy;
minimal when combined with
chemotherapy
Combretastatin
A-4-Phosphate (Zybrestat) [44]
Microtubule depolymerization
in endothelial cells, direct
cytotoxicity to AML cells
Preclinical
Combretastatin
A-1-Phosphate (OXi4503) [15]
Microtubule depolymerization
in endothelial cells, direct
cytotoxicity to AML cells
Phase 1 Ongoing
leukemia cells by two proposed mechanisms: ﬁrst, when
considering that AML myeloblasts can express VEGF iso-
forms and VEGFR2, anti-VEGF therapies may have a direct
inhibitory eﬀect on malignant myeloblasts. Second, VEGF
is an important factor in the angiogenesis of the leukemia
niche. Therefore, it was reasoned that bevacizumab may
result in AML regression in patients. Two clinical studies
of bevacizumab in relapsed and refractory AML have been
reported [34, 35]. Dr. Karp and colleagues at Johns Hopkins
conducted a phase II clinical study of bevacizumab using a
timed sequential therapy approach in 48 patients with either
relapsed or refractory AML. Cytarabine was administered
on days1–4, followed by 40–60 minutes of mitoxantrone,
and ﬁnally bevacizumab on day 8. Serum VEGF levels
were elevated prior to bevacizumab infusion on day 8 and
decreased markedly after infusion. The clinical outcomes of
this time sequential therapy showed complete response in
33% of patients, partial response in 15%, and no response
in 35%. In the 33% of patients with complete response,
the median disease-free survival was about 7 months. These
clinical outcomes in a heavily pretreated group are higher
than expected with chemotherapy alone and suggest an
additive eﬀect of bevacizumab in remitting disease. In the
second study, Mesters and colleagues assessed the activity
and eﬃcacy of single agent bevacizumab in a small trial of
9 patients with relapsed and refractory AML. In their study,
VEGF expression in the bone marrow was decreased after
bevacizumab; however, there was no decrease in VEGFR2
and VEGFR2y, suggesting little inhibition of their phos-
phorylation activity. Furthermore, despite reduced VEGF
expression in the bone marrow, there was no signiﬁcant
decrease in blast count after bevacizumab monotherapy.
Indeed, we have found similar ﬁndings of minimal beneﬁt
in preclinical models of AML [15]. Overall, there is low
enthusiasm for single agent bevacizumab in AML. However,
anti-VEGF-A antibodies may be useful in combination with
other chemotherapeutic or vascular disrupting agents.
Another agent that binds and targets the VEGF ligand,
and with higher aﬃnity than bevacizumab, is aﬂibercept
VEGF trap. This fusion protein binds to VEGF-A, VEGF-B,
andplacentalgrowthfactor(PlGF).Aﬂibercepthasonlybeen
evaluated in solid tumors for tolerability and shows modest
antitumor activity [36]. In AML, the study of aﬂibercept has
been restricted to human AML through in vitro and mouse
xenograft models. The preliminary in vivo studies of Lal et
al. showed that aﬂibercept slowed disease progression in two
systemic human AML mouse xenograft models. Combining
aﬂibercept with doxorubicin enhanced antileukemia eﬀects,
decreased microvessels, and induced perivascular apoptosis
[46].
Another strategy in targeting VEGF activity is to tar-
get VEGFRs. In speciﬁc, small molecule tyrosine kinase
inhibitors (TKIs) have been designed to impair VEGFR
phosphorylation activity.
Vatalanib, active against VEGFRs and PDGFRs, is well
tolerated and has shown clinical activity in multiple solid
t u m o r s .V a t a l a n i bh a sb e e nt e s t e di nA M La n dM D S .
A two-armed phase I clinical trial of dose-escalated vatalanib
showed that the agent is well tolerated in AML and MDS
patients with minimal side eﬀects [43]. Hypertension was
reported and mitigated by medical management. A vata-
lanib dose of 750mg by mouth daily was established as6 Journal of Oncology
themaximumtolerateddose(MTD).Whilethesafetyproﬁle
for this TKI is favorable, the clinical eﬃcacy of Arm 1
monotherapy showed no signiﬁcant response to treatment,
with the greatest eﬃcacy in 2 patients that had prolonged
disease stabilization. Combination therapy resulted in 5
completeremissionevents.Thisstudysupportstherecurring
theme of minimal eﬃcacy in terms of monotherapy small-
molecule TKIs in the treatment of AML.
Cediranib, which was designed with even greater aﬃnity
for VEGFR-1 and VEGFR-2, has also shown clinical activity
in certain solid tumors such as glioblastoma multiforme
and nonsmall cell lung cancer [47, 48]. This TKI also in-
hibits receptor signaling at nanomolar ranges against c-kit,
PDGFR-β, and VEGFR-3. In AML, a phase I clinical study
of cediranib in 35 leukemia patients showed a correlation
between cediranib exposure and plasma VEGF levels and
dose- and time-dependent reductions of soluble VEGFR-
2[ 37]. Also, although there was no connection between
clinical activity and microvessel density from treatment, the
majority of patients who received the maximum tolerated
dose(30mg/day)didshowsigniﬁcantdecreasesintheirbone
marrow MVD. In terms of clinical response, only modest
beneﬁt was reported. Only four patients out of 31 evaluable
subjects showed an objective response. Taking this into
consideration, future clinical studies will consider cediranib
at 20mg and 30mg in combination with standard induction
chemotherapies to improve clinical eﬃcacy.
In AML, activating mutations in FLT3, especially internal
tandem duplications, predict for a higher chance for refrac-
tory and relapsed disease. Thus, the current standard of care
is to refer patients with FLT3 mutant AML for allogeneic
hematopoietic cell transplant (allo-HCT), as this is the only
potential for cure. However, few older AML patients are
candidates for allo-HCT because of comorbidities, difﬁ-
culties in ﬁnding a donor and ﬁnancial/insurance reasons.
Therefore, attempts have been made to target FLT3 activity
with inhibitors.
Sorafenib, a TKI designed to target Ras-Raf/MEK/ERK
signaling, but also targets FLT3, has shown clinical activity in
renal cell carcinoma and hepatocellular carcinoma [49, 50].
Given that approximately 30% of AML patients have an acti-
vating FLT3 mutation, sorafenib was recently tested in AML
patients to establish feasibility [39]. Metzelder et al. adminis-
tered sorafenib in 8 AML patients (FLT3 mutant) between
2007 and 2010. All patients showed rapid hematological
responsesandcompletemolecularremissionswereobserved.
The study is ongoing and longer followup is needed and
planned [40]. On a much larger scale, Serve et al. conducted
amulticenter,randomized,placebo-controlled,double-blind
trial of this sorafenib in AML. Investigators administered
oral sorafenib versus placebo in combination with standard
induction chemotherapy (seven days of cytarabine and three
days of idarubicin chemotherapy followed by two cycles of
intermediate dose AraC consolidation therapy in 197 AML
patients over the age of 60 [41]). One hundred two patients
received sorafenib (400mg daily) and 95 patients received
placebo. Hand-foot-skin reactions which were commonly
seen in early phase solid tumor trials were also observed in
a few AML patients (n = 5) receiving sorafenib. Prior to
the consolidation AraC cycles, there was a trend in slower
regenerationofleukocytesandthrombocytesinthesorafenib
arm. However, in terms of clinical response, there were no
improvements in event-free survival and overall survival
compared to the placebo group. This trial suggests that while
targeting FLT3 with sorafenib is tolerable in AML, it shows
little clinical activity.
Sunitinib (SU11248) is another angio-inhibitory TKI
that has been tested as an antineoplastic agent [37]. In
addition to targeting c-Kit, VEGFRs, and PDGFRs, sunitinib
also inhibits FLT3. This inhibition proﬁle, therefore, made
sunitinibanattractiveagentforAML—especiallyforpatients
with high risk FLT3 activating mutation. In a phase I study of
15 patients with refractory AML, patients received sunitinib
50mg daily. No dose limiting toxicities occurred. Adverse
events were limited to grade 2 edema, fatigue, and oral
ulcerations. There were two fatal hemorrhages, which were
potentially related to underlying disease. Escalating the dose
to 75mg resulted in grade 4 toxicities of fatigue, hyperten-
sion, and cardiac failure and led to the abandonment of
the dose level. In terms of eﬃcacy, there were only partial
responses of short duration. Levels of both plasma VEGF
and plasma FLT3 ligand (FL) signiﬁcantly increased from
baseline in most of the 16 evaluated patients with no corre-
lation to clinical responses. The signiﬁcance of VEGF plasma
level increases has been reported in other clinical studies and
may owe itself to the hypoxic induction of VEGF, whereas
the signiﬁcance of FL has yet to be determined. Given the
adverse events at low doses of sunitinib and minimal clinical
response, there is low enthusiasm to continue testing this
TKIasamonotherapyagent.However,thismultitargetagent
may enhance response to other agents such as chemotherapy
and/or vascular disrupting agents.
The small-molecule TKI semaxanib (SU5416) targets
the common VEGF receptors 1 and 2, cKit, and FLT3. In
a multicenter phase 2 trial of semaxanib, 42 patients with
advanced, c-kit positive AML, either refractory or elderly
patients not ﬁt for intensive induction chemotherapy,
received at least one dose of treatment [38]. At a dose of
145mg/m2 twice a week, the drug was well tolerated, with
mostly mild to moderately severe adverse events. The most
striking adverse event, not seen in solid tumor studies of
semaxanib, was severe bone pain, which may be attributed
to the activity of the drug in bone marrow. Of 25 patients
who were evaluable for clinical response, 1 patient achieved a
morphological response followed by a relapse after 8 weeks,
and 7 of the 25 patients achieved partial response with
decreases in bone marrow and peripheral blood leukemic
blasts of at least 50%. In terms of biological response,
VEGF levels and bone marrow MVD correlated with each
other and decreased after semaxanib treatment. Again, the
modest clinical activity of this small-molecule TKI dampens
enthusiasm for monotherapy in AML. However, the agent
did show biological activity and this merits further study,
including combination therapy.
Due to their multitargeted potential, TKIs could open
the door to more personalized cancer treatments. However,
many are metabolized through hepatic cytochrome P450
enzymes and have the potential to interact with manyJournal of Oncology 7
medications commonly prescribed to patients with AML
(e.g., antifungal agents such as azoles and chemotherapy). It
is conceivable that in the future, AML cell surface expression
or genetic mutation may dictate what type of TKI to
prescribe. This is particularly attractive in older patients with
AML who may be ineligible for high intensity chemotherapy.
Theseolderpatientsma yfar ebetterwithanoralTKIandlo w
intensity chemotherapy.
Our own studies have led further eﬀorts to develop
multitargeted therapies. Our lab has identiﬁed a promis-
ing multi-target antivascular treatment strategy, using a
novel endothelial cell targeting agent, combretastatin A-1
(OXi4503) [15], alone and in combination with beva-
cizumab. Combretastatins were discovered in the 1970s
from the South African Bush Willow. These agents are
structurally similar to colchicine and, like colchicine, bind
to β-tubulin, lead to microtubule depolymerization and
selectively target rapidly proliferating ECs. Unlike colchicine,
combretastatinsexhibitvasculardisruptionbelowmaximum
tolerated dose (MTD). Therefore, these agents are highly
attractive for clinical translation. We and others have
shown that naturally occurring combretastatins, CA4 and
CA1, potently regress AML in xenograft models. We also
showed that the combretastatin CA1 results in a VEGF-
driven reactive angiogenesis which supports disease relapse.
Therefore we devised a strategy to combine combretastatin
(CA1) and anti-VEGF antibodies (bevacizumab). This novel
strategy resulted in potent regression of AML. We therefore
translated this work into a phase I clinical study of CA1
(OXi4503) in patients with relapsed and refractory AML
and MDS (ClinicalTrials.gov Identiﬁer NCT01085656). After
establishing MTD, we plan to combine combretastatins with
other angio-inhibitor agents like bevacizumab in future
clinical trials.
6. SummaryandFutureDirections
Whereas cancer angiogenesis is classically thought of in con-
text to solid tumors, there is mounting evidence that angio-
genesis is also signiﬁcant in leukemia. With speciﬁc regard
to leukemia and endothelial cells, there are several aspects
to consider. First, endothelial cells can support leukemia
cells via secreted factors. Whereas a few key axes have been
identiﬁed (e.g., VEGF/VEGFR and Ang-1/2/Tie2), the full
panoply of secreted factors has yet to be deﬁned. Second,
leukemiacellscanpromoteendothelialcells.Theobservation
of a codependent relationship creating a vicious cycle of
support substantiates the strategy of using endothelial cell
targeting agents such as combretastatins. Third, studies
identifying critical adhesion molecules between leukemia
and endothelial cells are lacking, and this represents an open
area of research. These studies will enlighten us of how
leukemia cells enter and exit the bone marrow. Understand-
ing how sinusoidal endothelial cells—gatekeeper cells of the
marrow—regulate emigration and immigration will lead to
novel strategies for mobilizing leukemia out of protective
niches and towards heightened sensitivity to treatment.
Fourth,leukemiacellscancoexpressendothelialcellfeatures.
How these features impact sensitivity and protection from
conventional treatment need to be better elucidated. Part
of these studies will involve inhibiting endothelial cell-
associated expression, and it will be important to determine
whether this inhibition results in increased sensitivity to
treatment. If so, then this would represent a novel strategy
for sensitizing leukemia-EC hybrids to treatment. Fifth, the
vascular niche in the bone marrow contains many other
cell types. Two in particular, perivascular pericytes and
intercalated megakaryocytes, participate in the way that the
sinusoidal vessels regulate hematopoietic stem and progeni-
tor cell function. Therefore, it is reasonable to consider these
other cells types as important players in the governance of
leukemia behavior. Finally, beyond cell types, there are many
noncellular elements of the bone marrow microenvironment
that need to be assessed. These bone marrow conditions
include chronic physiological hypoxia, low pH, low glucose
levels, and extracellular matrices. All of these factors aﬀect
angiogenesis and vice versa; therefore, these factors need to
be deﬁned in the context of leukemia pathology to have a
more complete picture of how the disease develops, responds
to treatment, and relapses.
One important clinical translation of a better under-
standing of the relationship between angiogenesis and
leukemia is in the realm of improved diagnostics. Currently
bone marrow biopsies and repeated blood draws are the
mainstay for diagnosis, prognosis, and response assessment.
With advent of new biologics that have antiangiogenic and
antivascular activity, there is a calling for novel biomark-
ers and methods to measure response and predict for
responders. Through the development of a pre-treatment
biomarker screening method, we may be able to utilize exist-
ingandfutureantiangiogenicagentstotheirfullpotentialon
a more personalized basis.
Another clinical translational consideration is how to
assess treatment response after administering vascular tar-
geting agents in AML. Currently, there are no established
methods. Consider that the primary target is bone marrow
blood vessels, it would reason to follow that changes in bone
marrow vascularity indicate treatment response. However,
there are several methods to quantify bone marrow vascular
activity. Serial bone marrow biopsies for measurement of
microvessel density, EC function, and angiogenic cytoki-
nesare involve procedures that are painful and possibly
aﬀected by sampling area. Furthermore, histologic and
biochemical testing takes time and do not provide results
in real time. Another method to monitor bone marrow
blood vessel activity is via serial computed tomography (CT)
scans. However, this method exposes the patient to harmful
ionizing irradiation and intravenous contrast carries the
risk for nephrotoxic reactions. Magnetic resonance imaging
(MRI) is another method to measure changes in bone
marrow blood vessels. This method is rapid and does not
deliver harmful ionizing irradiation. Moreover, the risks of a
contrast (gadolinium) toxicity is lower than with CT scans.
Recently, two groups have shown early data that dynamic
contrast enhanced- (DCE-) MRI can be used to assess
bone marrow vascular perfusion and predict for response to
chemotherapy [51, 52].8 Journal of Oncology
The last clinical translational consideration is that many
of the vascular targeting clinical studies in AML have
lacked investigation of mechanisms of action. It is assumed
that the administered antivascular agents operated through
blood vessel targeting mechanisms, but without an accurate
measurement of response this theory has yet to be proven.
Thus, it is imperative that rationally designed biomarkers
be used to evaluate response to vascular targeting agents.
In addition, AML cells themselves can aberrantly express
an endothelial-like phenotype, and therefore may be direct
targets of vascular targeting agents.
Finally, deﬁning how leukemia exploits the bone marrow
vascular niche may lead to promising new therapeutics. We
have already translated the vascular disrupting agent, CA1P
(OXi4503), into the clinic, and there are many more on the
way. As with many antiangiogenic and antivascular agents,
cytopenias have been observed in early clinical studies.
This is to be expected considering the crosstalk between
angiogenesis and hematopoiesis. Therefore, the application
of these novel agents into the leukemia unit and clinic will
require careful administration and an “induction” mindset.
Blood product transfusions and prophylactic antibiotics will
likely be required in these AML patients. However, with
adequate support, these agents may show promising results
over time.
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